| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Neoplasms | 190 | 2024 | 3108 | 14.070 |
Why?
|
| Carcinoma, Transitional Cell | 72 | 2024 | 999 | 12.170 |
Why?
|
| Nephrectomy | 111 | 2023 | 798 | 12.150 |
Why?
|
| Ureteral Neoplasms | 52 | 2024 | 238 | 11.750 |
Why?
|
| Carcinoma, Renal Cell | 122 | 2024 | 2386 | 8.480 |
Why?
|
| Urologic Neoplasms | 24 | 2024 | 202 | 7.120 |
Why?
|
| Ureter | 28 | 2023 | 219 | 5.470 |
Why?
|
| Laparoscopy | 45 | 2016 | 1302 | 4.890 |
Why?
|
| Urinary Bladder Neoplasms | 45 | 2023 | 2431 | 4.240 |
Why?
|
| Nephroureterectomy | 15 | 2024 | 48 | 3.490 |
Why?
|
| Robotics | 14 | 2016 | 365 | 2.980 |
Why?
|
| Kidney | 31 | 2024 | 2121 | 2.650 |
Why?
|
| Lymph Node Excision | 23 | 2024 | 2062 | 2.630 |
Why?
|
| Catheter Ablation | 17 | 2016 | 575 | 2.410 |
Why?
|
| Kidney Pelvis | 14 | 2023 | 114 | 2.160 |
Why?
|
| Prostatectomy | 14 | 2021 | 1003 | 2.080 |
Why?
|
| Mitomycin | 10 | 2023 | 213 | 1.990 |
Why?
|
| Cryosurgery | 9 | 2021 | 196 | 1.780 |
Why?
|
| von Hippel-Lindau Disease | 7 | 2018 | 121 | 1.720 |
Why?
|
| Cystectomy | 13 | 2021 | 635 | 1.710 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 4 | 2019 | 481 | 1.480 |
Why?
|
| Ureteroscopy | 13 | 2024 | 52 | 1.430 |
Why?
|
| Male | 210 | 2024 | 128315 | 1.410 |
Why?
|
| Humans | 305 | 2024 | 270740 | 1.400 |
Why?
|
| Watchful Waiting | 4 | 2018 | 293 | 1.370 |
Why?
|
| Urinary Bladder | 7 | 2021 | 593 | 1.350 |
Why?
|
| Urothelium | 10 | 2024 | 264 | 1.350 |
Why?
|
| Antibiotics, Antineoplastic | 4 | 2021 | 742 | 1.330 |
Why?
|
| Aged | 146 | 2024 | 73333 | 1.290 |
Why?
|
| Ablation Techniques | 4 | 2021 | 149 | 1.270 |
Why?
|
| Middle Aged | 165 | 2024 | 90352 | 1.240 |
Why?
|
| Carcinoma in Situ | 4 | 2018 | 489 | 1.150 |
Why?
|
| Neoplasms, Second Primary | 8 | 2021 | 1388 | 1.140 |
Why?
|
| Female | 185 | 2024 | 148940 | 1.140 |
Why?
|
| Retrospective Studies | 98 | 2024 | 39890 | 1.070 |
Why?
|
| Neoplasm Recurrence, Local | 36 | 2023 | 10400 | 1.020 |
Why?
|
| Neoplasm Staging | 41 | 2024 | 14012 | 1.010 |
Why?
|
| Nomograms | 5 | 2024 | 312 | 0.990 |
Why?
|
| Glomerular Filtration Rate | 5 | 2024 | 592 | 0.990 |
Why?
|
| Carcinoma | 7 | 2021 | 2610 | 0.970 |
Why?
|
| Pyrroles | 10 | 2016 | 588 | 0.970 |
Why?
|
| Treatment Outcome | 81 | 2024 | 33737 | 0.950 |
Why?
|
| Aged, 80 and over | 68 | 2024 | 30998 | 0.940 |
Why?
|
| Urinary Tract | 4 | 2023 | 86 | 0.930 |
Why?
|
| Venous Thrombosis | 4 | 2022 | 379 | 0.910 |
Why?
|
| Cytoreduction Surgical Procedures | 11 | 2023 | 510 | 0.900 |
Why?
|
| Urologic Surgical Procedures | 10 | 2016 | 93 | 0.900 |
Why?
|
| Indoles | 10 | 2016 | 1028 | 0.870 |
Why?
|
| Quality of Life | 9 | 2017 | 4761 | 0.810 |
Why?
|
| Chylous Ascites | 1 | 2022 | 25 | 0.800 |
Why?
|
| Prostatic Neoplasms | 15 | 2021 | 5866 | 0.790 |
Why?
|
| Warm Ischemia | 4 | 2014 | 21 | 0.750 |
Why?
|
| Neoplasms, Multiple Primary | 4 | 2021 | 557 | 0.750 |
Why?
|
| Uncertainty | 2 | 2013 | 328 | 0.750 |
Why?
|
| Angiogenesis Inhibitors | 8 | 2018 | 1269 | 0.730 |
Why?
|
| Prospective Studies | 30 | 2024 | 13414 | 0.720 |
Why?
|
| Urology | 7 | 2016 | 140 | 0.700 |
Why?
|
| Thrombectomy | 5 | 2022 | 167 | 0.680 |
Why?
|
| Penile Neoplasms | 3 | 2024 | 183 | 0.670 |
Why?
|
| Neoadjuvant Therapy | 17 | 2023 | 5231 | 0.660 |
Why?
|
| Penis | 2 | 2013 | 141 | 0.650 |
Why?
|
| Adjuvants, Immunologic | 3 | 2022 | 695 | 0.650 |
Why?
|
| Ultrasonography | 7 | 2018 | 1933 | 0.640 |
Why?
|
| Antineoplastic Agents | 21 | 2021 | 14617 | 0.630 |
Why?
|
| Angiomyolipoma | 2 | 2020 | 30 | 0.610 |
Why?
|
| Salvage Therapy | 2 | 2018 | 2123 | 0.610 |
Why?
|
| Retroperitoneal Space | 9 | 2022 | 156 | 0.580 |
Why?
|
| Image-Guided Biopsy | 2 | 2024 | 336 | 0.580 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 376 | 0.580 |
Why?
|
| Neoplasm Grading | 14 | 2021 | 1823 | 0.580 |
Why?
|
| Point-of-Care Testing | 1 | 2017 | 30 | 0.570 |
Why?
|
| Adult | 86 | 2024 | 82040 | 0.570 |
Why?
|
| Education, Medical, Graduate | 4 | 2017 | 705 | 0.570 |
Why?
|
| Lymphatic Metastasis | 14 | 2021 | 4963 | 0.570 |
Why?
|
| Ureteral Obstruction | 3 | 2023 | 146 | 0.560 |
Why?
|
| Cold Ischemia | 2 | 2014 | 23 | 0.560 |
Why?
|
| Videoconferencing | 2 | 2018 | 52 | 0.550 |
Why?
|
| Inguinal Canal | 4 | 2024 | 64 | 0.550 |
Why?
|
| Chemotherapy, Adjuvant | 16 | 2023 | 4000 | 0.530 |
Why?
|
| Maintenance Chemotherapy | 1 | 2017 | 226 | 0.520 |
Why?
|
| Endoscopy | 3 | 2018 | 496 | 0.510 |
Why?
|
| Multigene Family | 1 | 2017 | 469 | 0.510 |
Why?
|
| Adaptation, Psychological | 4 | 2017 | 787 | 0.490 |
Why?
|
| Adrenalectomy | 4 | 2011 | 195 | 0.470 |
Why?
|
| Survival Rate | 28 | 2021 | 12541 | 0.460 |
Why?
|
| Follow-Up Studies | 30 | 2021 | 15218 | 0.460 |
Why?
|
| Postoperative Care | 2 | 2016 | 728 | 0.460 |
Why?
|
| Induction Chemotherapy | 1 | 2017 | 670 | 0.460 |
Why?
|
| Neoplasm Invasiveness | 9 | 2021 | 4048 | 0.450 |
Why?
|
| Ischemic Preconditioning | 1 | 2013 | 21 | 0.440 |
Why?
|
| Video-Assisted Surgery | 1 | 2013 | 30 | 0.430 |
Why?
|
| Feasibility Studies | 12 | 2018 | 2353 | 0.420 |
Why?
|
| Patient Selection | 10 | 2020 | 2025 | 0.420 |
Why?
|
| Disease-Free Survival | 21 | 2021 | 10265 | 0.420 |
Why?
|
| Telemedicine | 3 | 2018 | 552 | 0.420 |
Why?
|
| Risk Factors | 32 | 2021 | 17888 | 0.410 |
Why?
|
| Pyrimidines | 3 | 2024 | 3669 | 0.410 |
Why?
|
| Acute Kidney Injury | 3 | 2013 | 761 | 0.400 |
Why?
|
| Vena Cava, Inferior | 3 | 2022 | 194 | 0.400 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 2 | 2024 | 67 | 0.390 |
Why?
|
| Neuroendocrine Tumors | 2 | 2016 | 656 | 0.390 |
Why?
|
| Risk Assessment | 23 | 2023 | 6764 | 0.390 |
Why?
|
| Sulfonamides | 2 | 2018 | 1933 | 0.390 |
Why?
|
| Pancreatectomy | 1 | 2016 | 696 | 0.370 |
Why?
|
| Peritoneum | 1 | 2011 | 151 | 0.360 |
Why?
|
| Robotic Surgical Procedures | 5 | 2024 | 533 | 0.360 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2016 | 861 | 0.350 |
Why?
|
| Cystoscopy | 2 | 2016 | 92 | 0.350 |
Why?
|
| Lymphoma, T-Cell | 1 | 2013 | 366 | 0.350 |
Why?
|
| Laparoscopes | 1 | 2009 | 11 | 0.350 |
Why?
|
| Everolimus | 3 | 2020 | 436 | 0.350 |
Why?
|
| Recovery of Function | 3 | 2012 | 681 | 0.340 |
Why?
|
| Kaplan-Meier Estimate | 19 | 2021 | 6256 | 0.340 |
Why?
|
| Cisplatin | 6 | 2023 | 2497 | 0.340 |
Why?
|
| Kidney Diseases | 4 | 2014 | 694 | 0.340 |
Why?
|
| Combined Modality Therapy | 13 | 2021 | 9039 | 0.340 |
Why?
|
| Proportional Hazards Models | 16 | 2021 | 5101 | 0.340 |
Why?
|
| Tomography, X-Ray Computed | 21 | 2017 | 7783 | 0.330 |
Why?
|
| Biopsy, Needle | 4 | 2010 | 1379 | 0.330 |
Why?
|
| Minimally Invasive Surgical Procedures | 7 | 2016 | 509 | 0.330 |
Why?
|
| Ischemia | 1 | 2012 | 400 | 0.330 |
Why?
|
| Thrombosis | 2 | 2018 | 743 | 0.320 |
Why?
|
| Nephrostomy, Percutaneous | 3 | 2018 | 58 | 0.320 |
Why?
|
| Administration, Topical | 3 | 2018 | 258 | 0.320 |
Why?
|
| Prostate | 3 | 2019 | 1089 | 0.320 |
Why?
|
| Sirolimus | 1 | 2013 | 831 | 0.320 |
Why?
|
| Genetic Testing | 1 | 2017 | 1696 | 0.320 |
Why?
|
| Kidney Function Tests | 5 | 2015 | 199 | 0.320 |
Why?
|
| Program Evaluation | 1 | 2011 | 603 | 0.310 |
Why?
|
| Biomarkers, Tumor | 8 | 2021 | 10708 | 0.300 |
Why?
|
| Hemostasis, Surgical | 1 | 2008 | 55 | 0.300 |
Why?
|
| Microsatellite Instability | 3 | 2019 | 408 | 0.300 |
Why?
|
| Predictive Value of Tests | 6 | 2024 | 4960 | 0.300 |
Why?
|
| Teaching | 1 | 2009 | 250 | 0.300 |
Why?
|
| Phenylurea Compounds | 3 | 2024 | 600 | 0.300 |
Why?
|
| Learning | 1 | 2011 | 431 | 0.290 |
Why?
|
| Postoperative Complications | 13 | 2023 | 5681 | 0.290 |
Why?
|
| Photochemotherapy | 1 | 2008 | 116 | 0.290 |
Why?
|
| Neoplasm Seeding | 2 | 2021 | 66 | 0.290 |
Why?
|
| Hernia, Ventral | 1 | 2009 | 163 | 0.290 |
Why?
|
| BCG Vaccine | 3 | 2021 | 428 | 0.280 |
Why?
|
| Diagnostic Imaging | 3 | 2010 | 1174 | 0.280 |
Why?
|
| Genomics | 2 | 2017 | 2835 | 0.280 |
Why?
|
| Endosonography | 1 | 2010 | 551 | 0.280 |
Why?
|
| Adrenal Gland Neoplasms | 6 | 2018 | 527 | 0.280 |
Why?
|
| Preoperative Period | 5 | 2019 | 346 | 0.280 |
Why?
|
| Prognosis | 29 | 2023 | 22505 | 0.270 |
Why?
|
| Texas | 11 | 2018 | 6449 | 0.260 |
Why?
|
| Writing | 3 | 2017 | 104 | 0.260 |
Why?
|
| Lymph Nodes | 5 | 2024 | 3077 | 0.260 |
Why?
|
| Radiography | 4 | 2013 | 1986 | 0.250 |
Why?
|
| Cohort Studies | 14 | 2020 | 9470 | 0.250 |
Why?
|
| Tertiary Care Centers | 2 | 2024 | 417 | 0.240 |
Why?
|
| Education, Medical, Continuing | 2 | 2009 | 231 | 0.240 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2018 | 5776 | 0.240 |
Why?
|
| Time Factors | 19 | 2021 | 13006 | 0.240 |
Why?
|
| Forearm | 1 | 2005 | 69 | 0.240 |
Why?
|
| Arteries | 1 | 2006 | 291 | 0.240 |
Why?
|
| Cell Dedifferentiation | 3 | 2020 | 100 | 0.230 |
Why?
|
| Patient Discharge | 2 | 2022 | 698 | 0.230 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2016 | 1828 | 0.230 |
Why?
|
| Sutures | 2 | 2013 | 93 | 0.230 |
Why?
|
| Biopsy | 9 | 2024 | 3484 | 0.230 |
Why?
|
| Hydrogels | 2 | 2021 | 134 | 0.220 |
Why?
|
| Solitary Kidney | 1 | 2023 | 2 | 0.220 |
Why?
|
| Pilot Projects | 4 | 2021 | 2828 | 0.220 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 3 | 2017 | 163 | 0.220 |
Why?
|
| Sarcoma, Synovial | 1 | 2005 | 141 | 0.220 |
Why?
|
| Heart Diseases | 1 | 2009 | 724 | 0.220 |
Why?
|
| Cyanoacrylates | 1 | 2003 | 38 | 0.220 |
Why?
|
| Urinary Diversion | 2 | 2010 | 86 | 0.220 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2018 | 637 | 0.220 |
Why?
|
| Pancreatic Neoplasms | 3 | 2016 | 5257 | 0.220 |
Why?
|
| Tissue Adhesives | 1 | 2003 | 47 | 0.220 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2023 | 16689 | 0.220 |
Why?
|
| Radiosurgery | 2 | 2024 | 1383 | 0.220 |
Why?
|
| Chordoma | 1 | 2005 | 170 | 0.210 |
Why?
|
| Renal Artery | 2 | 2016 | 87 | 0.210 |
Why?
|
| Tumor Burden | 7 | 2018 | 2033 | 0.210 |
Why?
|
| Pheochromocytoma | 4 | 2008 | 310 | 0.210 |
Why?
|
| Urogenital Neoplasms | 1 | 2003 | 115 | 0.210 |
Why?
|
| Survival Analysis | 11 | 2021 | 9292 | 0.210 |
Why?
|
| Urinary Reservoirs, Continent | 1 | 2002 | 39 | 0.200 |
Why?
|
| Enoxaparin | 1 | 2022 | 57 | 0.200 |
Why?
|
| Electromagnetic Phenomena | 1 | 2001 | 16 | 0.200 |
Why?
|
| Young Adult | 20 | 2021 | 22251 | 0.200 |
Why?
|
| Constriction, Pathologic | 4 | 2023 | 322 | 0.200 |
Why?
|
| Decompression, Surgical | 1 | 2002 | 144 | 0.200 |
Why?
|
| Intraoperative Care | 3 | 2018 | 274 | 0.200 |
Why?
|
| Lithotripsy | 1 | 2001 | 24 | 0.200 |
Why?
|
| Bone Neoplasms | 4 | 2020 | 2665 | 0.200 |
Why?
|
| Pelvic Neoplasms | 1 | 2023 | 199 | 0.190 |
Why?
|
| Hematoma | 1 | 2002 | 156 | 0.190 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2021 | 9042 | 0.190 |
Why?
|
| Catheterization | 2 | 2003 | 418 | 0.190 |
Why?
|
| Lymphocytes | 3 | 2020 | 1275 | 0.190 |
Why?
|
| Creatinine | 4 | 2023 | 529 | 0.190 |
Why?
|
| Mutation | 3 | 2019 | 15912 | 0.190 |
Why?
|
| Carcinogenesis | 2 | 2018 | 1033 | 0.190 |
Why?
|
| Tumor Microenvironment | 4 | 2023 | 3035 | 0.190 |
Why?
|
| Aftercare | 1 | 2022 | 252 | 0.180 |
Why?
|
| Nephrons | 3 | 2023 | 42 | 0.180 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2021 | 3409 | 0.180 |
Why?
|
| Iatrogenic Disease | 1 | 2022 | 195 | 0.180 |
Why?
|
| Dissection | 3 | 2018 | 132 | 0.180 |
Why?
|
| Lymphocele | 1 | 2000 | 11 | 0.180 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2020 | 2359 | 0.180 |
Why?
|
| CTLA-4 Antigen | 2 | 2021 | 678 | 0.180 |
Why?
|
| Lymphadenopathy | 1 | 2021 | 94 | 0.180 |
Why?
|
| Abdominal Wall | 1 | 2003 | 193 | 0.180 |
Why?
|
| Prostatic Hyperplasia | 1 | 2001 | 201 | 0.180 |
Why?
|
| Kidney Calculi | 1 | 2000 | 47 | 0.180 |
Why?
|
| Operative Time | 3 | 2019 | 255 | 0.170 |
Why?
|
| Vasovasostomy | 2 | 2004 | 25 | 0.170 |
Why?
|
| Retroperitoneal Neoplasms | 2 | 2015 | 296 | 0.170 |
Why?
|
| Interferon-alpha | 2 | 2003 | 959 | 0.170 |
Why?
|
| Pyridones | 1 | 2022 | 360 | 0.170 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2021 | 4961 | 0.170 |
Why?
|
| Neoplasm Metastasis | 12 | 2021 | 5315 | 0.170 |
Why?
|
| Deoxycytidine | 3 | 2023 | 1389 | 0.170 |
Why?
|
| Renal Veins | 3 | 2017 | 63 | 0.170 |
Why?
|
| Sensitivity and Specificity | 9 | 2019 | 5162 | 0.160 |
Why?
|
| Indazoles | 2 | 2018 | 310 | 0.160 |
Why?
|
| Radiology | 2 | 2021 | 426 | 0.160 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2019 | 76 | 0.160 |
Why?
|
| Margins of Excision | 2 | 2018 | 315 | 0.160 |
Why?
|
| Gene Expression Profiling | 8 | 2019 | 5149 | 0.160 |
Why?
|
| Laser Therapy | 1 | 2003 | 466 | 0.160 |
Why?
|
| Drug Carriers | 1 | 2020 | 336 | 0.160 |
Why?
|
| Glycemic Load | 1 | 2017 | 6 | 0.150 |
Why?
|
| Patient Satisfaction | 3 | 2017 | 917 | 0.150 |
Why?
|
| Glycemic Index | 1 | 2017 | 29 | 0.150 |
Why?
|
| Carbohydrates | 1 | 2017 | 55 | 0.150 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2005 | 927 | 0.150 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2017 | 41 | 0.150 |
Why?
|
| Intraoperative Period | 3 | 2020 | 251 | 0.150 |
Why?
|
| Ileostomy | 1 | 2018 | 47 | 0.150 |
Why?
|
| Mad2 Proteins | 1 | 2017 | 33 | 0.150 |
Why?
|
| Adolescent | 16 | 2018 | 32767 | 0.150 |
Why?
|
| Urinary Catheterization | 1 | 2018 | 135 | 0.150 |
Why?
|
| Ultrasonography, Interventional | 2 | 2018 | 424 | 0.150 |
Why?
|
| Neutrophils | 2 | 2020 | 873 | 0.140 |
Why?
|
| Case-Control Studies | 9 | 2018 | 6224 | 0.140 |
Why?
|
| Receptors, Leptin | 1 | 2017 | 67 | 0.140 |
Why?
|
| DNA Mismatch Repair | 1 | 2019 | 283 | 0.140 |
Why?
|
| Sequence Analysis, Protein | 1 | 2017 | 80 | 0.140 |
Why?
|
| Sequence Analysis, RNA | 2 | 2019 | 676 | 0.140 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2023 | 743 | 0.140 |
Why?
|
| Clinical Competence | 4 | 2009 | 1325 | 0.140 |
Why?
|
| Disease Models, Animal | 2 | 2010 | 7381 | 0.140 |
Why?
|
| Anticoagulants | 1 | 2022 | 775 | 0.140 |
Why?
|
| Antibodies, Monoclonal | 3 | 2020 | 4481 | 0.140 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2019 | 191 | 0.140 |
Why?
|
| Mutation Rate | 1 | 2017 | 220 | 0.130 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2019 | 242 | 0.130 |
Why?
|
| Expressed Emotion | 1 | 2016 | 19 | 0.130 |
Why?
|
| DNA Mutational Analysis | 3 | 2019 | 2357 | 0.130 |
Why?
|
| Age Factors | 5 | 2014 | 5457 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2024 | 7895 | 0.130 |
Why?
|
| Logistic Models | 7 | 2020 | 3444 | 0.130 |
Why?
|
| Niacinamide | 2 | 2016 | 428 | 0.130 |
Why?
|
| DNA Methylation | 2 | 2017 | 2765 | 0.130 |
Why?
|
| Incidence | 5 | 2021 | 5824 | 0.130 |
Why?
|
| Immunohistochemistry | 4 | 2017 | 7655 | 0.130 |
Why?
|
| Administration, Intravesical | 4 | 2020 | 169 | 0.130 |
Why?
|
| Meat | 1 | 2015 | 94 | 0.130 |
Why?
|
| Adrenal Glands | 1 | 2015 | 131 | 0.120 |
Why?
|
| Uroplakin III | 1 | 2014 | 8 | 0.120 |
Why?
|
| Quality Improvement | 1 | 2022 | 914 | 0.120 |
Why?
|
| Uroplakin II | 1 | 2014 | 15 | 0.120 |
Why?
|
| Adipose Tissue | 1 | 2019 | 715 | 0.120 |
Why?
|
| Testicular Neoplasms | 1 | 2019 | 560 | 0.120 |
Why?
|
| Pelvis | 3 | 2021 | 381 | 0.120 |
Why?
|
| Hepatomegaly | 1 | 2014 | 71 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 4 | 2018 | 2399 | 0.120 |
Why?
|
| Aneurysm, False | 1 | 2016 | 140 | 0.120 |
Why?
|
| Carcinoma, Medullary | 1 | 2016 | 248 | 0.120 |
Why?
|
| Mutagens | 1 | 2015 | 191 | 0.120 |
Why?
|
| Surveys and Questionnaires | 4 | 2013 | 5923 | 0.120 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2017 | 396 | 0.120 |
Why?
|
| Radiography, Interventional | 4 | 2011 | 311 | 0.120 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 751 | 0.120 |
Why?
|
| CpG Islands | 1 | 2017 | 671 | 0.120 |
Why?
|
| Perioperative Care | 2 | 2010 | 447 | 0.120 |
Why?
|
| Cluster Analysis | 1 | 2017 | 1075 | 0.120 |
Why?
|
| MicroRNAs | 2 | 2018 | 2887 | 0.120 |
Why?
|
| Caloric Restriction | 1 | 2014 | 88 | 0.120 |
Why?
|
| Epidemiologic Methods | 3 | 2010 | 254 | 0.120 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2014 | 691 | 0.120 |
Why?
|
| Metastasectomy | 1 | 2016 | 209 | 0.110 |
Why?
|
| Databases, Genetic | 1 | 2017 | 757 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2018 | 4644 | 0.110 |
Why?
|
| Doxorubicin | 3 | 2020 | 3145 | 0.110 |
Why?
|
| Pyrazoles | 1 | 2022 | 1546 | 0.110 |
Why?
|
| Risk | 5 | 2020 | 1939 | 0.110 |
Why?
|
| Prostate-Specific Antigen | 4 | 2021 | 1029 | 0.110 |
Why?
|
| Transcriptome | 3 | 2019 | 1963 | 0.110 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2017 | 628 | 0.110 |
Why?
|
| Medical Oncology | 4 | 2018 | 1465 | 0.110 |
Why?
|
| DNA, Mitochondrial | 1 | 2014 | 315 | 0.110 |
Why?
|
| Mucormycosis | 1 | 2014 | 118 | 0.100 |
Why?
|
| Ileum | 2 | 2023 | 167 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2015 | 426 | 0.100 |
Why?
|
| Ureterostomy | 1 | 2012 | 9 | 0.100 |
Why?
|
| Hemoglobins | 2 | 2020 | 482 | 0.100 |
Why?
|
| Professional Competence | 1 | 2013 | 139 | 0.100 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2012 | 49 | 0.100 |
Why?
|
| Sarcoma | 3 | 2020 | 1839 | 0.100 |
Why?
|
| Congresses as Topic | 1 | 2014 | 299 | 0.100 |
Why?
|
| Suture Techniques | 3 | 2009 | 292 | 0.100 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2016 | 706 | 0.100 |
Why?
|
| Hemangioblastoma | 1 | 2011 | 29 | 0.100 |
Why?
|
| Managed Care Programs | 1 | 2011 | 83 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2012 | 2650 | 0.100 |
Why?
|
| Chyle | 1 | 2011 | 22 | 0.100 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2015 | 442 | 0.100 |
Why?
|
| Signal Transduction | 5 | 2019 | 12103 | 0.100 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2015 | 678 | 0.100 |
Why?
|
| Neoplasm Transplantation | 2 | 2015 | 1553 | 0.090 |
Why?
|
| Embolization, Therapeutic | 1 | 2016 | 605 | 0.090 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2013 | 261 | 0.090 |
Why?
|
| Brachytherapy | 1 | 2017 | 1005 | 0.090 |
Why?
|
| Computational Biology | 1 | 2017 | 1291 | 0.090 |
Why?
|
| Depression | 3 | 2016 | 1730 | 0.090 |
Why?
|
| Stress, Psychological | 2 | 2017 | 1043 | 0.090 |
Why?
|
| Carcinoma, Papillary | 1 | 2014 | 566 | 0.090 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 2010 | 39 | 0.090 |
Why?
|
| Prednisone | 1 | 2013 | 1034 | 0.090 |
Why?
|
| Demography | 1 | 2011 | 433 | 0.090 |
Why?
|
| Emotions | 1 | 2014 | 560 | 0.090 |
Why?
|
| Lung Neoplasms | 4 | 2024 | 12033 | 0.090 |
Why?
|
| False Negative Reactions | 1 | 2010 | 291 | 0.080 |
Why?
|
| Diet | 1 | 2017 | 1477 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 984 | 0.080 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2010 | 131 | 0.080 |
Why?
|
| Rectal Neoplasms | 1 | 2018 | 1240 | 0.080 |
Why?
|
| Length of Stay | 3 | 2018 | 2007 | 0.080 |
Why?
|
| False Positive Reactions | 1 | 2010 | 375 | 0.080 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2008 | 127 | 0.080 |
Why?
|
| Obesity | 3 | 2017 | 2904 | 0.080 |
Why?
|
| Credentialing | 1 | 2009 | 61 | 0.080 |
Why?
|
| Surgical Instruments | 1 | 2009 | 141 | 0.080 |
Why?
|
| Odds Ratio | 4 | 2017 | 2311 | 0.080 |
Why?
|
| Body Mass Index | 3 | 2017 | 2232 | 0.080 |
Why?
|
| Vincristine | 1 | 2013 | 1583 | 0.080 |
Why?
|
| Blood Loss, Surgical | 2 | 2018 | 295 | 0.080 |
Why?
|
| Cell Cycle Proteins | 1 | 2017 | 2115 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2016 | 2471 | 0.080 |
Why?
|
| Office Visits | 1 | 2009 | 92 | 0.080 |
Why?
|
| Bevacizumab | 4 | 2015 | 967 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2012 | 1571 | 0.080 |
Why?
|
| Drug Administration Schedule | 3 | 2020 | 3530 | 0.080 |
Why?
|
| Reference Values | 2 | 2007 | 1133 | 0.080 |
Why?
|
| Internship and Residency | 2 | 2017 | 1452 | 0.080 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2011 | 2313 | 0.080 |
Why?
|
| Cognition | 1 | 2014 | 959 | 0.070 |
Why?
|
| Professional Practice | 1 | 2008 | 80 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2001 | 5002 | 0.070 |
Why?
|
| Comorbidity | 3 | 2015 | 2394 | 0.070 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2015 | 645 | 0.070 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 1568 | 0.070 |
Why?
|
| Ligation | 1 | 2008 | 206 | 0.070 |
Why?
|
| Telomere | 2 | 2009 | 550 | 0.070 |
Why?
|
| Fenretinide | 1 | 2008 | 100 | 0.070 |
Why?
|
| Phenotype | 2 | 2017 | 6509 | 0.070 |
Why?
|
| Equipment Failure | 1 | 2008 | 191 | 0.070 |
Why?
|
| Vinblastine | 2 | 2020 | 462 | 0.070 |
Why?
|
| Benzenesulfonates | 1 | 2008 | 196 | 0.070 |
Why?
|
| Stem Cell Transplantation | 1 | 2014 | 1418 | 0.070 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2014 | 1458 | 0.070 |
Why?
|
| Neoplasms | 3 | 2023 | 15927 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2001 | 5438 | 0.070 |
Why?
|
| Immunosuppressive Agents | 1 | 2013 | 1432 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2019 | 3949 | 0.070 |
Why?
|
| Societies, Medical | 3 | 2018 | 1320 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2010 | 1430 | 0.070 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2018 | 316 | 0.070 |
Why?
|
| Swine | 2 | 2008 | 1607 | 0.070 |
Why?
|
| Perioperative Period | 2 | 2018 | 149 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 2617 | 0.070 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2007 | 136 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 2 | 2023 | 558 | 0.070 |
Why?
|
| Pneumothorax, Artificial | 1 | 2005 | 6 | 0.060 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2024 | 689 | 0.060 |
Why?
|
| South Africa | 1 | 2005 | 109 | 0.060 |
Why?
|
| Safety | 1 | 2007 | 460 | 0.060 |
Why?
|
| Cyclophosphamide | 1 | 2013 | 3245 | 0.060 |
Why?
|
| Point Mutation | 1 | 2008 | 788 | 0.060 |
Why?
|
| Thalidomide | 1 | 2008 | 597 | 0.060 |
Why?
|
| Anastomosis, Surgical | 2 | 2023 | 370 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 1 | 2010 | 2454 | 0.060 |
Why?
|
| Methotrexate | 2 | 2020 | 1025 | 0.060 |
Why?
|
| Androgen Antagonists | 1 | 2007 | 420 | 0.060 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 2197 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2015 | 5408 | 0.060 |
Why?
|
| Quality Assurance, Health Care | 1 | 2009 | 596 | 0.060 |
Why?
|
| Organ Sparing Treatments | 2 | 2016 | 283 | 0.060 |
Why?
|
| Ifosfamide | 1 | 2005 | 358 | 0.060 |
Why?
|
| Postoperative Period | 2 | 2021 | 666 | 0.060 |
Why?
|
| Population Surveillance | 1 | 2007 | 647 | 0.060 |
Why?
|
| Remission Induction | 1 | 2010 | 3656 | 0.060 |
Why?
|
| Mitomycins | 1 | 2023 | 52 | 0.060 |
Why?
|
| Holmium | 1 | 2003 | 24 | 0.060 |
Why?
|
| Cytodiagnosis | 1 | 2024 | 201 | 0.060 |
Why?
|
| Oregon | 1 | 2023 | 15 | 0.060 |
Why?
|
| Pneumoperitoneum, Artificial | 1 | 2003 | 17 | 0.050 |
Why?
|
| Tensile Strength | 1 | 2003 | 76 | 0.050 |
Why?
|
| Erectile Dysfunction | 1 | 2006 | 239 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2005 | 307 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 3 | 2015 | 5759 | 0.050 |
Why?
|
| Animals | 7 | 2017 | 61956 | 0.050 |
Why?
|
| Wound Healing | 2 | 2009 | 749 | 0.050 |
Why?
|
| Abdominal Muscles | 1 | 2003 | 71 | 0.050 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2024 | 106 | 0.050 |
Why?
|
| Germ-Line Mutation | 1 | 2008 | 1101 | 0.050 |
Why?
|
| Reoperation | 3 | 2015 | 1392 | 0.050 |
Why?
|
| Cost Savings | 1 | 2003 | 123 | 0.050 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2003 | 127 | 0.050 |
Why?
|
| Chromosome Aberrations | 1 | 2009 | 2035 | 0.050 |
Why?
|
| Rhabdomyolysis | 1 | 2002 | 50 | 0.050 |
Why?
|
| Disease Progression | 4 | 2021 | 6867 | 0.050 |
Why?
|
| Diagnosis, Differential | 3 | 2014 | 4831 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2006 | 727 | 0.050 |
Why?
|
| Urinary Calculi | 1 | 2001 | 29 | 0.050 |
Why?
|
| Testosterone | 1 | 2007 | 638 | 0.050 |
Why?
|
| Renal Dialysis | 3 | 2006 | 917 | 0.050 |
Why?
|
| Vascular Neoplasms | 1 | 2003 | 112 | 0.050 |
Why?
|
| Morbidity | 1 | 2003 | 400 | 0.050 |
Why?
|
| Urethra | 1 | 2002 | 167 | 0.050 |
Why?
|
| Multivariate Analysis | 3 | 2015 | 4328 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 6177 | 0.050 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2021 | 1335 | 0.050 |
Why?
|
| Inflammation | 1 | 2011 | 2518 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2017 | 14849 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 3 | 2016 | 2400 | 0.050 |
Why?
|
| Interferon-Stimulated Gene Factor 3 | 1 | 2001 | 7 | 0.050 |
Why?
|
| Interferon-Stimulated Gene Factor 3, gamma Subunit | 1 | 2001 | 7 | 0.050 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2005 | 605 | 0.050 |
Why?
|
| Evidence-Based Medicine | 2 | 2018 | 1034 | 0.050 |
Why?
|
| Diagnostic Techniques, Urological | 1 | 2001 | 8 | 0.050 |
Why?
|
| Genome, Human | 1 | 2009 | 1888 | 0.050 |
Why?
|
| United States | 5 | 2020 | 15861 | 0.050 |
Why?
|
| Pyridines | 1 | 2008 | 1313 | 0.050 |
Why?
|
| Living Donors | 1 | 2001 | 175 | 0.050 |
Why?
|
| Interferon-beta | 1 | 2001 | 109 | 0.050 |
Why?
|
| Genital Diseases, Female | 1 | 2001 | 60 | 0.040 |
Why?
|
| Preoperative Care | 3 | 2012 | 1567 | 0.040 |
Why?
|
| Urodynamics | 1 | 2000 | 54 | 0.040 |
Why?
|
| Israel | 1 | 2020 | 62 | 0.040 |
Why?
|
| DNA Repair | 1 | 2008 | 1909 | 0.040 |
Why?
|
| Drug Compounding | 1 | 2020 | 73 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2006 | 1754 | 0.040 |
Why?
|
| Comparative Effectiveness Research | 1 | 2020 | 116 | 0.040 |
Why?
|
| Linear Models | 2 | 2014 | 1093 | 0.040 |
Why?
|
| Sex Factors | 2 | 2014 | 2184 | 0.040 |
Why?
|
| Genotype | 2 | 2018 | 4252 | 0.040 |
Why?
|
| Tuberous Sclerosis | 1 | 2020 | 145 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2018 | 2250 | 0.040 |
Why?
|
| Genome-Wide Association Study | 2 | 2018 | 2351 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 5593 | 0.040 |
Why?
|
| Peritoneal Dialysis | 1 | 2000 | 140 | 0.040 |
Why?
|
| Mice, Nude | 2 | 2015 | 4329 | 0.040 |
Why?
|
| Microsurgery | 2 | 2004 | 235 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2020 | 334 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2018 | 246 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 3844 | 0.040 |
Why?
|
| Neuropeptide Y | 1 | 2017 | 49 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2005 | 1302 | 0.040 |
Why?
|
| Mice | 3 | 2017 | 35600 | 0.040 |
Why?
|
| Dietary Fiber | 1 | 2017 | 127 | 0.040 |
Why?
|
| Stents | 1 | 2003 | 999 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2018 | 735 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2001 | 1111 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2015 | 1051 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2001 | 1179 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2018 | 729 | 0.030 |
Why?
|
| Interviews as Topic | 2 | 2009 | 521 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2018 | 384 | 0.030 |
Why?
|
| Chromosomal Instability | 1 | 2017 | 229 | 0.030 |
Why?
|
| Patient Safety | 1 | 2021 | 613 | 0.030 |
Why?
|
| Aneuploidy | 1 | 2017 | 382 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2015 | 84 | 0.030 |
Why?
|
| Transfection | 1 | 2001 | 3117 | 0.030 |
Why?
|
| Drug Delivery Systems | 2 | 2010 | 661 | 0.030 |
Why?
|
| Leptin | 1 | 2017 | 306 | 0.030 |
Why?
|
| Clinical Studies as Topic | 1 | 2014 | 19 | 0.030 |
Why?
|
| Quinoxalines | 1 | 2015 | 97 | 0.030 |
Why?
|
| Child | 3 | 2016 | 30559 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2018 | 581 | 0.030 |
Why?
|
| Gene-Environment Interaction | 1 | 2015 | 163 | 0.030 |
Why?
|
| Keratin-7 | 1 | 2014 | 48 | 0.030 |
Why?
|
| Decision Trees | 1 | 2015 | 181 | 0.030 |
Why?
|
| Neprilysin | 1 | 2014 | 60 | 0.030 |
Why?
|
| Hyphae | 1 | 2014 | 44 | 0.030 |
Why?
|
| Urologic Diseases | 1 | 2014 | 83 | 0.030 |
Why?
|
| Fellowships and Scholarships | 2 | 2009 | 411 | 0.030 |
Why?
|
| Monosomy | 1 | 2014 | 98 | 0.030 |
Why?
|
| Academic Medical Centers | 2 | 2008 | 681 | 0.030 |
Why?
|
| Embryo, Mammalian | 1 | 2017 | 746 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 772 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2015 | 1655 | 0.030 |
Why?
|
| Calcium | 1 | 2000 | 1578 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 1097 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2019 | 2090 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2017 | 7238 | 0.030 |
Why?
|
| Prevalence | 2 | 2015 | 3404 | 0.030 |
Why?
|
| Registries | 1 | 2021 | 2211 | 0.030 |
Why?
|
| Hydronephrosis | 1 | 2013 | 51 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2017 | 642 | 0.030 |
Why?
|
| Computer Systems | 1 | 2013 | 113 | 0.030 |
Why?
|
| Social Support | 1 | 2016 | 590 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2015 | 550 | 0.030 |
Why?
|
| Learning Curve | 1 | 2013 | 78 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2014 | 757 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2015 | 427 | 0.030 |
Why?
|
| Heterografts | 1 | 2015 | 738 | 0.030 |
Why?
|
| Leukocytes | 1 | 2014 | 421 | 0.030 |
Why?
|
| Ultrasound, High-Intensity Focused, Transrectal | 1 | 2012 | 7 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2015 | 593 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2016 | 1608 | 0.020 |
Why?
|
| China | 1 | 2013 | 636 | 0.020 |
Why?
|
| Genes, MHC Class II | 1 | 2011 | 71 | 0.020 |
Why?
|
| Insulin | 1 | 2017 | 1483 | 0.020 |
Why?
|
| Health Policy | 1 | 2014 | 278 | 0.020 |
Why?
|
| Insurance Claim Review | 1 | 2011 | 73 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2017 | 817 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2017 | 2137 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2008 | 17061 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2018 | 1470 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2017 | 1654 | 0.020 |
Why?
|
| NADPH Oxidases | 1 | 2011 | 146 | 0.020 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2011 | 109 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 1024 | 0.020 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2014 | 347 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2001 | 6390 | 0.020 |
Why?
|
| Urine | 1 | 2011 | 135 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2015 | 714 | 0.020 |
Why?
|
| Urinalysis | 1 | 2011 | 84 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2011 | 396 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2016 | 2580 | 0.020 |
Why?
|
| Sleep Wake Disorders | 1 | 2014 | 372 | 0.020 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2015 | 1032 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2017 | 3216 | 0.020 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2010 | 139 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 2 | 2009 | 953 | 0.020 |
Why?
|
| Imidazoles | 1 | 2015 | 1065 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2017 | 5694 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2014 | 2067 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2015 | 2422 | 0.020 |
Why?
|
| Adrenergic Antagonists | 1 | 2008 | 19 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 1 | 2012 | 359 | 0.020 |
Why?
|
| Contracts | 1 | 2008 | 9 | 0.020 |
Why?
|
| Time Management | 1 | 2008 | 15 | 0.020 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2008 | 105 | 0.020 |
Why?
|
| Contrast Media | 1 | 2015 | 1499 | 0.020 |
Why?
|
| Negotiating | 1 | 2008 | 14 | 0.020 |
Why?
|
| Private Practice | 1 | 2008 | 34 | 0.020 |
Why?
|
| B7-H1 Antigen | 1 | 2015 | 1089 | 0.020 |
Why?
|
| Job Application | 1 | 2008 | 20 | 0.020 |
Why?
|
| Hypertension | 1 | 2017 | 1591 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2009 | 398 | 0.020 |
Why?
|
| Laser Scanning Cytometry | 1 | 2007 | 15 | 0.020 |
Why?
|
| Mitochondria | 1 | 2014 | 1297 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 1199 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2011 | 964 | 0.020 |
Why?
|
| Fatigue | 1 | 2014 | 1275 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 749 | 0.020 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2008 | 176 | 0.020 |
Why?
|
| Placebos | 1 | 2008 | 442 | 0.020 |
Why?
|
| Specialization | 1 | 2008 | 128 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 3917 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2007 | 274 | 0.020 |
Why?
|
| Mass Screening | 1 | 2015 | 1552 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 1312 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2010 | 2315 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 1281 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2010 | 1824 | 0.020 |
Why?
|
| Electrodes | 1 | 2005 | 132 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2011 | 1624 | 0.020 |
Why?
|
| Exons | 1 | 2008 | 1383 | 0.010 |
Why?
|
| Quinazolines | 1 | 2009 | 956 | 0.010 |
Why?
|
| Kinetics | 1 | 2007 | 2220 | 0.010 |
Why?
|
| Adenoma | 1 | 2009 | 740 | 0.010 |
Why?
|
| Pedigree | 1 | 2008 | 2042 | 0.010 |
Why?
|
| Kidney Calices | 1 | 2003 | 8 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 3658 | 0.010 |
Why?
|
| Apoptosis | 1 | 2017 | 7757 | 0.010 |
Why?
|
| Tissue Expansion | 1 | 2003 | 71 | 0.010 |
Why?
|
| Base Sequence | 1 | 2008 | 5437 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 4958 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2004 | 1697 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 4821 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2008 | 6685 | 0.010 |
Why?
|
| Equipment Design | 1 | 2004 | 1197 | 0.010 |
Why?
|
| Biomarkers | 1 | 2012 | 5051 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2011 | 3438 | 0.010 |
Why?
|
| Cell Line | 1 | 2007 | 5338 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 4372 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 2001 | 761 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2008 | 3557 | 0.010 |
Why?
|